Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis
NCT04472546 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210
Last updated 2024-06-07
Summary
The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic is affected. It is thus possible to follow a change in the state of the skin by looking at change in the associated molecular profile.
The PRISM laboratory (INSERM U1192) in Lille has developed an innovative system laser called SpiderMass composed of 4 parts:
1. A laser used for the micro-sampling of material in vivo,
2. A transport transfer line of the ablated particles,
3. A mass spectrometer that analyzes them in real time and generates the molecular profiles of the epidermis,
4. A data analysis procedure.
The SpiderMass(TM) is of great interest for the study of the skin because it allows non-invasive vivo characterization, and therefore without biopsy or sample preparation. In addition, it will complement techniques already used in the research center such as FTIR spectroscopy. Indeed, in acne studies the FTIR allows to obtain only the Fatty Acid Triglycerid ratio while the SpiderMass permits to detail these lipid classes by each observed molecule on the surface of the skin and follow their evolution.
Conditions
- Acne
- Atopic Dermatitis
- Psoriasis Vulgaris
- Rosacea
- Seborrheic Dermatitis
- Healthy
Interventions
- OTHER
-
in-vivo mesure
* for acne of the face subgroup and its associated control : face and inner side of the forearm * for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm * for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm * for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm * for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm
- OTHER
-
Scotch
* for acne of the face subgroup and its associated control : face and inner side of the forearm * for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm * for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm * for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm * for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm
- OTHER
-
Lipid index
* for acne of the face subgroup and its associated control : face * for seborrheic dermatitis of scalp subgroup and its associated control: scalp * for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face
- OTHER
-
Absorbant paper
* for acne of the face subgroup and its associated control : face * for seborrheic dermatitis of scalp subgroup and its associated control: scalp * for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead
- OTHER
-
Hydratation Index
-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
- OTHER
-
TransEpidermal Water Loss
-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
Sponsors & Collaborators
-
Pierre Fabre Dermo Cosmetique
lead INDUSTRY
Principal Investigators
-
Thérèse NOCERA, Mrs · Centre de Recherche sur La Peau
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-12-13
- Primary Completion
- 2023-02-02
- Completion
- 2024-02-02
Countries
- France
Study Locations
More Related Trials
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01355458 ·Status: COMPLETED ·Phase: PHASE3
-
A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea
NCT01614743 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01355471 ·Status: COMPLETED ·Phase: PHASE3
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
NCT05942248 ·Status: RECRUITING ·Phase: NA
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea
NCT01789775 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate the Safety and Effectiveness of the Treatment With Tixel C on Acne Scars
NCT04269317 ·Status: WITHDRAWN ·Phase: NA
-
Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias
NCT02761174 ·Status: COMPLETED ·Phase: PHASE4
-
Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
NCT02217228 ·Status: COMPLETED ·Phase: NA
-
Imiquimod in Children With Plaque Morphea
NCT00147771 ·Status: COMPLETED ·Phase: PHASE3
-
Exploratory Study Evaluating the Effects of Dermo-cosmetic RV5026B Applied for 2 Months in Adults With Erythrocouperosis
NCT06824870 ·Status: TERMINATED ·Phase: NA
-
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
NCT01453179 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris
NCT02066545 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients
NCT01688531 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
NCT02998671 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
NCT04856917 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ
NCT00189254 ·Status: COMPLETED
-
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
NCT00211497 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of 30% Salicylic Acid and 10% Nicotinamide Combined Therapy in Melasma
NCT07062120 ·Status: COMPLETED ·Phase: NA
-
Comparison of Two Salicylic Acid Formulations
NCT00848744 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea
NCT02583009 ·Status: COMPLETED ·Phase: PHASE2
-
Investigating the Safety and Efficacy of the 1927-nm Thulium Laser in Keratosis Pilaris
NCT07078461 ·Status: RECRUITING ·Phase: NA
-
A Pilot Study Testing the Effects of Chemical Peels in Patients With Rosacea
NCT04889703 ·Status: WITHDRAWN ·Phase: NA
-
Combined Salicylic and Azaleic Acid Verus Trichloroacetic Acid 25% Peel in Treatment of Acne
NCT03071549 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis
NCT02716714 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars
NCT02126657 ·Status: UNKNOWN ·Phase: PHASE2